Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with <i>ALK-</i>positive non-small cell lung cancer (NSCLC).

Camidge, D. Ross; Bang, Yung‐Jue; Kwak, Eunice L.; Shaw, Alice T.; Iafrate, A. John; Maki, Robert G.; Solomon, Benjamin J.; Ou, S-H.I.; Salgia, Ravi; Wilner, Keith D.; Costa, Daniel B.; Shapiro, G.; LoRusso, P.; Stephenson, P.; Tang, Yi; Ruffner, Katherine; Clark, J. W.

doi:10.1200/jco.2011.29.15_suppl.2501

Cited by 117 publications

(113 citation statements)

References 0 publications

Supporting

Mentioning

110

Contrasting

Order By: Relevance

“…Identification of certain mutations would allow molecularly targeted agents to be given to patients in attempt to improve outcomes. For example, crizotinib is used in patients with locally advanced or metastatic non-small cell lung cancer positive for the ALK gene rearrangement, [31][32][33] and could therefore be tried in patients with ALK mutations and CUPs of possible lung origin. The panel noted, however, that data in the CUP setting for such an approach are lacking.…”

Section: Testing For Actionable Mutationsmentioning

confidence: 99%

Occult Primary, Version 3.2014

Ettinger

Handorf

Agulnik³

et al. 2014

J Natl Compr Canc Netw

View full text Add to dashboard Cite

The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation. (J Natl Compr Canc Netw 2014;12:969-974) Occult Primary, Version 3.2014 CE Authors:Deborah J. Moonan, RN, BSN, Director, Continuing Education & Grants, NCCN, has disclosed that she has no relevant financial relationships. Ann Gianola, MA, Manager, Continuing Education & Grants, NCCN, has disclosed that she has no relevant financial relationships. Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships. Individuals Who Provided Content Development and/or Authorship Assistance:David S. Ettinger, MD, panel chair, has disclosed that he has no relevant financial relationships. Charles R. Handorf, MD, PhD, panel vice-chair, has disclosed that he has no relevant financial relationships. Mary Anne Bergman, Guidelines Coordinator, has disclosed that she has no relevant financial relationships. Deborah A. Freedman-Cass, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.

show abstract

Section: Testing For Actionable Mutationsmentioning

confidence: 99%

Occult Primary, Version 3.2014

Ettinger

Handorf

Agulnik³

et al. 2014

J Natl Compr Canc Netw

View full text Add to dashboard Cite

show abstract

“…An update of the pivotal phase-I trial with this agent reported on 119 mostly heavily pretreated patients. The median progressionfree survival and the one-and two-year survival were 10 months, 70% and 55%, respectively, which by far exceeds anything previously observed [25]. Results from randomised crizotinib trials in pretreated or chemotherapy naïve are eagerly awaited.…”

Section: Eml4-alk Gene Rearrangementmentioning

confidence: 71%

Targeted therapy in non-small cell lung cancer

Putora

Schneider

Rodriguez

et al. 2012

Breathe

View full text Add to dashboard Cite

“…39 The data from this ongoing trial were subsequently updated to include 119 ALK-positive NSCLC patients enrolled with a data cutoff of October 29, 2010. 40 The baseline clinicopathologic features that emerged from this trial reflected the unique characteristics previously reported in NSCLC tumors with ALK gene rearrangement. Of the 119 patients enrolled on trial, the median age was 51 (range 21-79) years.…”

Section: Clinical Experience With Alk Inhibition In Lung Cancermentioning

confidence: 92%

“…Ninety-seven percent of the 119 enrolled NSCLC patients with ALK gene rearrangements had tumors with adenocarcinoma histology, frequently with the presence of signet ring cells. 40 In the initial report of 82 patients with ALK-rearranged NSCLCs treated with crizotinib, the response rate was 57%, with multiple patients experiencing clinical improvement and disease shrinkage within several weeks of starting drug. 39 In the updated series of 119 patients, 86% of whom had received at least one prior line of therapy for advanced disease survival in this heavily pretreated cohort of 119 patients was 10.0 months (95% CI 8.2-14.7) with 50 events (42%; 40 progressive disease events), 69 patients (58%) censored, and 59/69 (86%) in follow-up for progression-free survival.…”

Section: Clinical Experience With Alk Inhibition In Lung Cancermentioning

confidence: 99%

Targeted inhibition in tumors with ALK dependency

Kwak¹,

Clark²,

Shaw³

2013

LCTT

View full text Add to dashboard Cite

Abstract:The oncogenic function of gene translocations involving the anaplastic lymphoma kinase (ALK) was first reported in rare subtypes of non-Hodgkin's lymphoma almost two decades ago. More recently, aberrant ALK signaling was found to be an oncogenic driver in subsets of non-small cell lung cancer (NSCLC), particularly in patients with little or no tobacco smoking history. The advent of molecularly targeted therapies that inhibit ALK has allowed the pairing of ALK inhibitors such as crizotinib as treatment for ALK-positive NSCLC, yielding dramatic responses and long-term disease control. The clinicopathologic features of ALK-driven NSCLC, the clinical development of ALK inhibitors, and the genetic determinants of acquired resistance to ALK inhibition are among the topics covered in this review.

show abstract

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Cited by 117 publications

References 0 publications

Occult Primary, Version 3.2014

Occult Primary, Version 3.2014

Targeted therapy in non-small cell lung cancer

Targeted inhibition in tumors with ALK dependency

Contact Info

Product

Resources

About